Cargando…
PB2554: DESIGN OF A PHASE 1B OPEN-LABEL STUDY TO ASSESS THE SAFETY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF POVETACICEPT (ALPN-303) IN SUBJECTS WITH AUTOIMMUNE CYTOPENIAS (RUBY-4)
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429011/ http://dx.doi.org/10.1097/01.HS9.0000976912.69182.0b |
| _version_ | 1785090608870719488 |
|---|---|
| author | Broome, Catherine M Arnold, Donald Piatek, Caroline Lee, Eun-Ju Zayed, Hany Peng, Stanford Simsek, Ismail |
| author_facet | Broome, Catherine M Arnold, Donald Piatek, Caroline Lee, Eun-Ju Zayed, Hany Peng, Stanford Simsek, Ismail |
| author_sort | Broome, Catherine M |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10429011 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104290112023-08-17 PB2554: DESIGN OF A PHASE 1B OPEN-LABEL STUDY TO ASSESS THE SAFETY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF POVETACICEPT (ALPN-303) IN SUBJECTS WITH AUTOIMMUNE CYTOPENIAS (RUBY-4) Broome, Catherine M Arnold, Donald Piatek, Caroline Lee, Eun-Ju Zayed, Hany Peng, Stanford Simsek, Ismail Hemasphere Publication Only Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10429011/ http://dx.doi.org/10.1097/01.HS9.0000976912.69182.0b Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Publication Only Broome, Catherine M Arnold, Donald Piatek, Caroline Lee, Eun-Ju Zayed, Hany Peng, Stanford Simsek, Ismail PB2554: DESIGN OF A PHASE 1B OPEN-LABEL STUDY TO ASSESS THE SAFETY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF POVETACICEPT (ALPN-303) IN SUBJECTS WITH AUTOIMMUNE CYTOPENIAS (RUBY-4) |
| title | PB2554: DESIGN OF A PHASE 1B OPEN-LABEL STUDY TO ASSESS THE SAFETY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF POVETACICEPT (ALPN-303) IN SUBJECTS WITH AUTOIMMUNE CYTOPENIAS (RUBY-4) |
| title_full | PB2554: DESIGN OF A PHASE 1B OPEN-LABEL STUDY TO ASSESS THE SAFETY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF POVETACICEPT (ALPN-303) IN SUBJECTS WITH AUTOIMMUNE CYTOPENIAS (RUBY-4) |
| title_fullStr | PB2554: DESIGN OF A PHASE 1B OPEN-LABEL STUDY TO ASSESS THE SAFETY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF POVETACICEPT (ALPN-303) IN SUBJECTS WITH AUTOIMMUNE CYTOPENIAS (RUBY-4) |
| title_full_unstemmed | PB2554: DESIGN OF A PHASE 1B OPEN-LABEL STUDY TO ASSESS THE SAFETY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF POVETACICEPT (ALPN-303) IN SUBJECTS WITH AUTOIMMUNE CYTOPENIAS (RUBY-4) |
| title_short | PB2554: DESIGN OF A PHASE 1B OPEN-LABEL STUDY TO ASSESS THE SAFETY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF POVETACICEPT (ALPN-303) IN SUBJECTS WITH AUTOIMMUNE CYTOPENIAS (RUBY-4) |
| title_sort | pb2554: design of a phase 1b open-label study to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of povetacicept (alpn-303) in subjects with autoimmune cytopenias (ruby-4) |
| topic | Publication Only |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429011/ http://dx.doi.org/10.1097/01.HS9.0000976912.69182.0b |
| work_keys_str_mv | AT broomecatherinem pb2554designofaphase1bopenlabelstudytoassessthesafetyefficacypharmacokineticsandpharmacodynamicsofpovetaciceptalpn303insubjectswithautoimmunecytopeniasruby4 AT arnolddonald pb2554designofaphase1bopenlabelstudytoassessthesafetyefficacypharmacokineticsandpharmacodynamicsofpovetaciceptalpn303insubjectswithautoimmunecytopeniasruby4 AT piatekcaroline pb2554designofaphase1bopenlabelstudytoassessthesafetyefficacypharmacokineticsandpharmacodynamicsofpovetaciceptalpn303insubjectswithautoimmunecytopeniasruby4 AT leeeunju pb2554designofaphase1bopenlabelstudytoassessthesafetyefficacypharmacokineticsandpharmacodynamicsofpovetaciceptalpn303insubjectswithautoimmunecytopeniasruby4 AT zayedhany pb2554designofaphase1bopenlabelstudytoassessthesafetyefficacypharmacokineticsandpharmacodynamicsofpovetaciceptalpn303insubjectswithautoimmunecytopeniasruby4 AT pengstanford pb2554designofaphase1bopenlabelstudytoassessthesafetyefficacypharmacokineticsandpharmacodynamicsofpovetaciceptalpn303insubjectswithautoimmunecytopeniasruby4 AT simsekismail pb2554designofaphase1bopenlabelstudytoassessthesafetyefficacypharmacokineticsandpharmacodynamicsofpovetaciceptalpn303insubjectswithautoimmunecytopeniasruby4 |